Compare Schlumberger NV (SLB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs Vertex Pharmaceuticals Incorporated — how do they compare? Schlumberger NV trades at $48.94 (market cap $71.18B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Schlumberger NV pays a 2.46% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Schlumberger NV for 99 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SLB | VRTX | |
|---|---|---|
Market Cap | $71.18B | $128.16B |
Volume | 14,872,321 | 806,603 |
Sector | Energy | Health |
52-Week High | $60.10 | $557.96 |
52-Week Low | $31.72 | $407.37 |
Typical Hold Time | 99 Days | 120 Days |
Enterprise Value | $79.91B | $122.29B |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $48.98, down 2.04% with bearish technical signals despite strong analyst support. The company maintains solid profitability with 8.53% net margin and 13.37% ROE, though recent revenue and earnings show slight contraction. Recent contract wins in Saudi Arabia, Oman, and Mozambique provide multi-year revenue visibility and expansion in key energy markets.
Wall Street remains bullish with 85% buy ratings and $64.58 price target implying 32% upside. However, declining profit margins and bearish technical indicators suggest near-term pressure. The stock offers value at current levels for investors comfortable with energy sector volatility and execution risks on new contracts.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
